GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anxo Pharmaceutical Co Ltd (ROCO:6677) » Definitions » Capex-to-Operating-Cash-Flow

Anxo Pharmaceutical Co (ROCO:6677) Capex-to-Operating-Cash-Flow : 0.00 (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Anxo Pharmaceutical Co Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Anxo Pharmaceutical Co's Capital Expenditure for the six months ended in Jun. 2023 was NT$-27.17 Mil. Its Cash Flow from Operations for the six months ended in Jun. 2023 was NT$-7.04 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Anxo Pharmaceutical Co Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Anxo Pharmaceutical Co's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anxo Pharmaceutical Co Capex-to-Operating-Cash-Flow Chart

Anxo Pharmaceutical Co Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.33 0.45 0.27 0.43 0.22

Anxo Pharmaceutical Co Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.02 0.14 0.69 0.12 -

Competitive Comparison of Anxo Pharmaceutical Co's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Anxo Pharmaceutical Co's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anxo Pharmaceutical Co's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anxo Pharmaceutical Co's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Anxo Pharmaceutical Co's Capex-to-Operating-Cash-Flow falls into.



Anxo Pharmaceutical Co Capex-to-Operating-Cash-Flow Calculation

Anxo Pharmaceutical Co's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-15.772) / 71.423
=0.22

Anxo Pharmaceutical Co's Capex-to-Operating-Cash-Flow for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-27.174) / -7.037
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anxo Pharmaceutical Co  (ROCO:6677) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Anxo Pharmaceutical Co Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Anxo Pharmaceutical Co's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Anxo Pharmaceutical Co (ROCO:6677) Business Description

Traded in Other Exchanges
N/A
Address
8th Floor-3, Nanjing East Road, No. 206, Section 2, Taipei City, TWN
Anxo Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in developing drugs which include prescription medication and consumer healthcare medication. The products of the company include cardiovascular system medication, central nervous system medication, diabetes medication, infectious medicine, and dermatology medication.

Anxo Pharmaceutical Co (ROCO:6677) Headlines

No Headlines